VASODILATOR ACTION OF GUINEA-PIG VASOACTIVE INTESTINAL POLYPEPTIDE (VIP) - COMPARISON WITH COMMON MAMMALIAN VIP

被引:5
|
作者
NARUSE, S [1 ]
INOUE, T [1 ]
MOCHIZUKI, T [1 ]
YANAIHARA, N [1 ]
机构
[1] UNIV SHIZUOKA, SCH PHARMACEUT SCI, SHIZUOKA, JAPAN
关键词
VASOACTIVE INTESTINAL POLYPEPTIDE; GUINEA PIG; DOG; BLOOD PRESSURE; PANCREATIC BLOOD FLOW; FEMORAL ARTERY; OXIDATION;
D O I
10.1016/0167-0115(92)90096-D
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The vascular activity of guinea pig (gp) and common mammalian (p) VIP were compared in anesthetized guinea pigs and dogs. In the guinea pig, intravenous injections of gpVIP and pVIP increased pancreatic blood flow and reduced the systemic arterial pressure and pancreatic vascular resistance in a dose-related manner. There were no significant differences in the vasodilator actions of these two VIPs, indicating that the overall cardiovascular actions of gpVIP and pVIP are similar in guinea pigs. In the dog, gpVIP, when given intra-arterially, was less potent (about 1/4) than pVIP in its action on femoral blood flow, suggesting that the blood vessels of the dog hind leg are more sensitive to its own VIP than to gpVIP. Oxidation of pVIP and gpVIP with H2O2 greatly reduced their vasodilator effects on the femoral arterial blood flow. The vascular effects were restored to control levels by reduction of the oxidized peptides with mercaptoethanol which suggests that methionine residues of gpVIP and pVIP are important in the vasodilator effect on the femoral arterial bed in dogs.
引用
下载
收藏
页码:163 / 171
页数:9
相关论文
共 50 条
  • [21] COMPARISON OF MAMMALIAN VIP BIOACTIVITIES IN DISPERSED ACINI FROM GUINEA-PIG PANCREAS
    RAUFMAN, JP
    ENG, J
    DU, BH
    STRAUS, E
    YALOW, RS
    REGULATORY PEPTIDES, 1986, 14 (01) : 93 - 97
  • [22] DIFFERENT MECHANISMS OF ACTION OF VASOACTIVE INTESTINAL POLYPEPTIDE (VIP) AND GLUCAGON ON INTESTINAL SECRETION
    MAILMAN, D
    GASTROENTEROLOGY, 1977, 73 (06) : 1463 - 1465
  • [23] RADIOIMMUNOASSAY OF VASOACTIVE INTESTINAL POLYPEPTIDE (VIP) IN PLASMA
    FAHRENKRUG, J
    SCHAFFALITZKYDEMUCKADELL, OB
    JOURNAL OF LABORATORY AND CLINICAL MEDICINE, 1977, 89 (06): : 1379 - 1388
  • [24] VASOACTIVE-INTESTINAL-PEPTIDE (VIP) MODULATES INJURY CAUSED BY PARAQUAT IN GUINEA-PIG LUNGS
    PAKBAZ, H
    FODA, HD
    BERISHA, HI
    SAID, SI
    CLINICAL RESEARCH, 1990, 38 (02): : A440 - A440
  • [25] PHARMACOLOGY OF VASOACTIVE INTESTINAL POLYPEPTIDE (VIP) IN ACHALASIA
    ROSSITER, A
    GUELRUD, M
    SOUNEY, PF
    FANIKOS, J
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1991, 49 (02) : 172 - 172
  • [26] The significance of vasoactive intestinal polypeptide (VIP) in immunomodulation
    Bellinger, DL
    Lorton, D
    Brouxhon, S
    Felten, S
    Felten, DL
    ADVANCES IN NEUROIMMUNOLOGY, 1996, 6 (01): : 5 - 27
  • [27] VASOACTIVE INTESTINAL POLYPEPTIDE (VIP) AND PERIPHERAL VASODILATATION
    OTTESEN, B
    SCHROEDER, T
    BJARNESEN, J
    CHRISTOFFERSEN, JK
    ACTA PHARMACOLOGICA ET TOXICOLOGICA, 1985, 56 (02): : 191 - 192
  • [28] VASOACTIVE INTESTINAL POLYPEPTIDE (VIP) IN VASOMOTOR RHINITIS
    KURIAN, SS
    BLANK, MA
    SHEPPARD, MN
    STANLEY, PJ
    MACKAY, IS
    COLE, PJ
    BLOOM, SR
    POLAK, JM
    IRCS MEDICAL SCIENCE-BIOCHEMISTRY, 1983, 11 (05): : 425 - 426
  • [29] VASOACTIVE INTESTINAL POLYPEPTIDE (VIP) - CURRENT STATUS
    SAID, SI
    PEPTIDES, 1984, 5 (02) : 143 - 150
  • [30] IS VASOACTIVE INTESTINAL POLYPEPTIDE (VIP) A SLEEP FACTOR
    DRUCKERCOLIN, R
    BERNALPEDRAZA, J
    FERNANDEZCANCINO, F
    OKSENBERG, A
    PEPTIDES, 1984, 5 (04) : 837 - 840